Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Soon catalysts of THTX?

<< Previous

Bullboard Posts

Next >>

Comment by Spartrapon Mar 17, 2021 9:28am

103 Views

Post# 32815218

RE:RE:RE:RE:RE:Soon catalysts of THTX?

Wino115 wrote:
We've never heard of a delay yet. But I do know from following various other trials that to put together a global (possibly) trial with 30-40 sites, all the testing and signups, etc... can't be easy.

You are very far from the mark. With a global average of 0.45 (US) to 0.2 (EU) pts/center/month enrollment in NASH, it's a bare minimum of 150 sites that need to be opened if one wants to enroll 900 pts (and then 1100 more!) in finite time.

<< Previous

Bullboard Posts

Next >>

Eminent acquires promising Nevada gold project